CRISPR's Second Decade: The First Wave of Approved Gene Editing Medicines

CRISPR gene editing crossed its most important milestone yet in late 2023 when the FDA approved Casgevy — the first CRISPR-based medicine — for sickle cell disease and beta thalassemia. That approval, jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals, turned a decade of laboratory promise into a licensed drug that patients can actually receive. The question now isn't whether CRISPR medicines work. It's whether the healthcare system can deliver them to the people who need them.

The first generation of approvals has revealed both the extraordinary precision gene editing can achieve and the brutal economics of bringing it to patients. CRISPR's second decade will be defined less by scientific breakthroughs and more by the harder problems of manufacturing scale, delivery mechanisms, and cost structures that determine who benefits and who doesn't.

What Casgevy Actually Does

Casgevy targets the root cause of sickle cell disease rather than managing its symptoms. The treatment works ex-vivo: doctors extract stem cells from the patient's bone marrow, edit them outside the body to reactivate fetal hemoglobin production (by knocking out the BCL11A enhancer), then infuse the corrected cells back after chemotherapy wipes out the patient's existing marrow. The edited cells repopulate the bone marrow and produce functional hemoglobin, eliminating the sickling that causes vaso-occlusive crises and organ damage.

Clinical trial results were striking. In Vertex's trial of patients with severe sickle cell disease, 28 of 29 patients who completed follow-up were free of vaso-occlusive crises for at least 12 consecutive months. For beta thalassemia, 39 of 42 evaluable patients no longer needed blood transfusions. These are not incremental improvements — for many patients, this represents a functional cure.

The price reflects that: $2.2 million for sickle cell disease, $3.1 million for beta thalassemia — among the highest drug prices ever set. Vertex and CRISPR Therapeutics argue the one-time cost is offset by a lifetime of avoided hospitalizations, transfusions, and disease management. That math works on paper, but insurance systems and healthcare budgets weren't designed to process seven-figure single treatments.

The Manufacturing and Access Bottleneck

As of mid-2026, Casgevy is approved in the United States, UK, EU, Saudi Arabia, and Bahrain, but the number of patients who have actually received treatment remains far below the addressable population. The limiting factor isn't regulatory approval — it's the infrastructure required to deliver it.

The treatment requires authorized treatment centers (ATCs) that can perform apheresis (stem cell collection), the chemotherapy conditioning regimen, and the subsequent cell infusion. Each manufacturing run is patient-specific: cells are collected, shipped to a central manufacturing facility, edited, quality-tested, then shipped back for infusion. The entire process takes roughly 6–8 months from enrollment to treatment. About 75 treatment centers were authorized in the US as of early 2026, concentrated in major academic medical centers — leaving patients in rural areas or developing countries with severe access barriers.

The sickle cell disease population in the United States is roughly 100,000 people, with an estimated 20,000–30,000 who have severe enough disease to be candidates for Casgevy. Getting even a fraction of them treated at current manufacturing capacity and cost will take years.

In-Vivo CRISPR: The Next Frontier

Ex-vivo approaches like Casgevy require stem cell extraction and conditioning chemotherapy — major clinical procedures that limit which patients can receive treatment. The more ambitious goal is in-vivo gene editing: delivering CRISPR components directly into the body, where they find and edit target cells without requiring cells to leave the patient.

Intellia Therapeutics is the furthest along in this space. Its lead candidate NTLA-2001 (now called nexiguran ziclumeran, or nex-z) targets transthyretin amyloidosis (ATTR), a condition caused by a misfolded liver protein that deposits in the heart and nerves. The drug delivers CRISPR-Cas9 via lipid nanoparticles (LNPs) directly to the liver, where it knocks out the TTR gene. Phase 3 results published in 2025 showed a 93% median reduction in serum TTR after a single dose — persistent for at least 18 months of follow-up. Regulatory submission is expected in late 2026.

The LNP delivery system works well for the liver because LNPs naturally accumulate there after intravenous injection. Editing other tissues — muscle, brain, lung — requires different delivery approaches that remain in earlier development. Adeno-associated viruses (AAVs) can reach more tissue types but face immune challenges and have strict cargo size limits. Getting CRISPR to the brain remains one of the field's hardest open problems.

Base Editing and Prime Editing: More Precision, Fewer Cuts

Classical CRISPR-Cas9 cuts both strands of DNA — a blunt instrument that works but can cause unintended insertions or deletions at the cut site. The next generation of gene editing tools makes more precise changes without breaking the double helix entirely.

Base editing, pioneered by David Liu's lab at the Broad Institute and commercialized through Beam Therapeutics, chemically converts one DNA base to another (C-to-T or A-to-G) without making double-strand cuts. About half of disease-causing point mutations could theoretically be corrected this way. Beam's lead programs target sickle cell disease and beta thalassemia with base-editing approaches it believes will have a better safety profile than classical Cas9 cutting.

Prime editing, also from Liu's lab, is more versatile still: it can correct all 12 types of point mutations and make small insertions or deletions with high precision, using a modified Cas9 fused to a reverse transcriptase and guided by a "pegRNA." Prime Medicine, the company commercializing prime editing, entered Phase 1/2 trials in 2025 for a rare childhood skin disorder, with other programs following. The technology is more complex to deliver but theoretically capable of correcting a much wider range of mutations than base editing or classical CRISPR.

The Pipeline Beyond Blood Disorders

The approved medicines are concentrated in blood disorders because hematopoietic stem cells (HSCs) are relatively easy to extract, edit, and return. The broader pipeline is testing CRISPR against a much wider disease landscape:

• Cancer: Allogeneic CAR-T therapies using CRISPR-edited donor T cells (Caribou Biosciences, Precision BioSciences). Avoids the need to manufacture patient-specific cells.
• Cardiovascular: PCSK9 knockout for hypercholesterolemia (Intellia, Verve Therapeutics base editing). A single treatment to permanently lower LDL cholesterol.
• Infectious disease: Excising latent HIV from infected cells (Excision BioTherapeutics, EBT-101 Phase 1/2).
• Inherited blindness: In-vivo subretinal delivery (Editas Medicine, Intellia) for Leber congenital amaurosis and other retinal dystrophies.
• Muscular dystrophy: Exon skipping via base editing for Duchenne muscular dystrophy (Beam Therapeutics).

Each program faces its own delivery challenge. Blood disorders benefit from the accessibility of HSCs. Cardiovascular programs targeting the liver are unlocked by LNP delivery. Muscle and neurological conditions require approaches still in earlier stages.

What It Means for Healthcare Investors and Payers

The fundamental tension in CRISPR medicine's second decade is between the one-time cure model and the systems built around chronic disease management. Insurers pay claims monthly and cover patients who may switch providers. A $2 million cure that saves $200,000/year in disease costs is financially rational over a decade, but no single insurer is confident they'll cover the same patient for 10 years to recoup that benefit.

Several novel payment models are being tested: outcomes-based contracts where manufacturers refund costs if the therapy fails, installment payment arrangements, and blended government/payer risk pools for rare disease. None has scaled. The approval of Casgevy has forced this conversation into boardrooms it previously hadn't reached, and the resolution will shape how the next wave of gene therapies reaches patients.

Actionable Takeaways

• Watch Intellia's ATTR submission (late 2026): Nex-z would be the first in-vivo CRISPR medicine approved, unlocking in-vivo approaches for a much broader disease range.
• Track Beam and Prime Medicine Phase 2 readouts (2026–2027): Next-gen editing tools may eventually displace classical Cas9 if safety advantages hold in clinical data.
• The bottleneck is delivery, not editing: Companies that solve tissue-specific in-vivo delivery will define the next era. LNP optimization and AAV alternatives (lipid nanoparticles for non-liver tissues, engineered viral capsids) are where the frontier sits.
• Payer and manufacturing scale will determine whether this stays rare: The science has outpaced the healthcare infrastructure. Expect regulatory and policy focus on treatment center authorization, manufacturing standards, and alternative payment structures through 2028.
• CRISPR diagnostics are moving fast too: SHERLOCK and DETECTR platforms (CRISPR-based nucleic acid detection) are reaching commercial diagnostic applications — a lower-profile but near-term commercial opportunity separate from therapeutics.